Medtronic today announced it has applied artificial intelligence to all Reveal LINQ™ ICM devices in the United States, Australia and New Zealand through a cloud-based update.

Medtronic launched the Reveal LINQ ICM in 2014; since then, health care providers have used this technology to help more than 750,000 patients around the world. Now, health care providers who use Reveal LINQ to help people with arrythmias have access to artificial intelligence algorithms (AccuRhythm™ AI) that reduce false alerts and improve information accuracy.

Medtronic anticipates the addition of AccuRhythm AI algorithms on the Reveal LINQ ICM will result in a cumulative reduction of 85% in false alerts for atrial fibrillation (AF) and pause, while preserving true alerts at a rate of 98.2% and 99.9%, respectively.ⁱ  This saves clinics more than 186 hours of false alert review per year for every 200 Reveal LINQ ICM patients, which allows time for clinicians to focus on more critical patient care activities.ⁱⁱ

“This milestone is both a nod to the past as we celebrate the thousands of patients who have benefited from Reveal LINQ over the last decade, and a glimpse into the future as an example of how AI can effectively update an established technology overnight,” said Stacey Churchwell, vice president and general manager, Cardiovascular Diagnostics and Services within the Cardiac Rhythm Management business, which is part of the Cardiovascular Portfolio at Medtronic.

Medtronic developed its first insertable cardiac monitor more than 25 years ago with the release of Reveal™ Insertable Loop Recorder (ILR) in 1998. Since then, new iterations have brought improvements in both size and capabilities. The introduction of Reveal LINQ in 2014 revolutionized the ICM space given its significantly smaller size profile than earlier ICMs, with advanced sensors to detect AF more accurately, and other arrhythmias that may be associated with syncope or other symptoms.

The AccuRhythm AI update for the Reveal LINQ ICM will also be available in Europe later this year.

The AccuRhythm AI platform applies deep learning AI algorithms to Reveal LINQ ICM data flowing into the CareLink™ network to remove a high percentage of false AF and false pause episodes and significantly reduce clinic review burden. Medtronic developed the AccuRhythm AI platform and initial algorithms using its database of more than 1 million electrocardiogram heart rhythm episodes. AccuRhythm AI is applied in the cloud automatically with no action required of patients.

AccuRhythm AI initially received FDA market clearance for use with LINQ II ICMs in June 2021 and in April 2023 for use with Reveal LINQ ICMs. Learn more about AccuRhythm AI algorithms.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com, and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Joey Lomicky
Public Relations
+1-612-239-1823

Ryan Weispfenning
Investor Relations
+1-763-505-4626